Search Videos and More
News
Dana-Farber/Boston Children's Ranked Among the Best Pediatric Cancer Programs in the Nation for 18th Year in a Row
U.S. News & World Report has again recognized Dana-Farber/Boston Children's Cancer and Blood Disorders Center as the #2 pediatric cancer program in the nation in its 2024-25 Best Children's Hospitals report.
News
Dana-Farber Cancer Institute Leads the Launch of IGNITE Consortium to Eradicate Health Inequities in Pediatric Cancer Care
In a bold step toward addressing the stark disparities in pediatric cancer care, Dana-Farber Cancer Institute is taking the lead in launching IGNITE—the first national, pediatric hematology-oncology health equity research consortium.
News
Study Identifies Novel Target for Pediatric Neuroblastoma
Researchers at Dana-Farber Cancer Institute have identified a protein complex that is required for the growth of a high-risk form of childhood brain cancer called MYCN-amplified neuroblastoma.
News
Telehealth Can Significantly Reduce Greenhouse Gas Emissions Associated with Cancer Care, Study Finds
Telemedicine visits for cancer care may not only be more convenient and easier to schedule than in-person appointments, they're also better for the planet, new research by Dana-Farber Cancer Institute scientists shows.
News
Science Behind Targeted Drug for Pediatric Brain Cancer Has Dana-Farber Roots
Two separate research teams had discovered a genetic driver for the most common of childhood brain tumors called pediatric low-grade glioma.
News
Dana-Farber Cancer Institute Researchers Join Global Cancer Grand Challenges Team Taking on Solid Tumors in Children
Dana-Farber Cancer Institute's Scott Armstrong, MD, PhD, Benjamin Ebert, MD, PhD, Eric Fischer, PhD, Cigall Kadoch, PhD, and Kimberly Stegmaier, MD, are part of a global, interdisciplinary team of researchers, called Team PROTECT, that has been selected to receive a Cancer Grand Challenges award. The award, of up to $25 million over five years, will be used to tackle solid tumors in children.
News
Dana-Farber/Boston Children's Again Ranked Among the Best Pediatric Cancer Programs in the Nation
U.S. News & World Report has named Dana-Farber/Boston Children's Cancer and Blood Disorders Center the #2 pediatric program in the nation in its 2023-24 Best Children's Hospitals report.
News
Three of the World’s Top Research Institutions Join Forces to Drive Progress Against Pediatric Cancer
Large-scale collaboration will leverage each institution’s expertise and infrastructure to advance understanding of the biological basis of pediatric cancers, identify new vulnerabilities of these diseases and accelerate cures globally.
News
Study Shows That Genomic Tumor Profiling of Pediatric Tumors Can Enhance Clinical Care
Results of a study of molecular tumor profiling in young patients revealed a high rate of genetic alterations with potential for impacting clinical care, including clarifying diagnoses and treatment with matched, precision cancer drugs.
News
Dana-Farber/Boston Children's Again Named Top Pediatric Cancer Program
U.S. News & World Report has named Dana-Farber/Boston Children's Cancer and Blood Disorders Center #1 in the nation in its 2022-23 Best Children's Hospitals report. Dana-Farber/Boston Children's has been recognized as one of the top three pediatric cancer centers in the country each year since the ranking's inception, earning more #1 rankings than any other program.
News
Race, Ethnicity, and Poverty Linked to Worse Outcomes in Children Treated for High-Risk Neuroblastoma
Children with high-risk neuroblastoma had worse outcomes if they were from certain racial/ethnic groups or were on public rather than private insurance, despite being treated in clinical trials with standardized protocols, according to a study led by investigators from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.
News
Researchers Identify Promising Drug Target in Pediatric Neuroblastoma
Dana-Farber scientists have now teased apart the relationship between the proteins EP300 and CBP — to discover that EP300 is critical for a high-risk form of pediatric neuroblastoma.